Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
ESMO Open|November 16, 2016
Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohortJacques Bonneterre, Jacques Bosq, Philippe Jamme, et al.
Molecular Endocrinology (Baltimore, Md.)|March 11, 2014
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cellsGwen E Dressing, Todd P Knutson, Matthew J Schiewer, et al.
Molecular Cancer Research : MCR|January 20, 2018
Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 ComplexesThu H Truong, Hsiangyu Hu, Nuri A Temiz, et al.
Cancer Research|January 31, 2016
Breast Tumor Kinase (Brk/PTK6) Is Induced by HIF, Glucocorticoid Receptor, and PELP1-Mediated Stress Signaling in Triple-Negative Breast CancerTarah M Regan Anderson, Shi Hong Ma, Ganesh V Raj, et al.
Hormones & Cancer|July 16, 2011
2-Methoxyestradiol inhibits progesterone-dependent tissue factor expression and activity in breast cancer cellsMarisol Quezada, Jorge Diaz, Soledad Henriquez, et al.
BMC Cancer|March 18, 2017
Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cellsYao Huang, David J Burns, Benjamin E Rich, et al.
Molecular Cancer Research : MCR|November 11, 2020
Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) SignalingAmy R Dwyer, Carlos Perez Kerkvliet, Raisa I Krutilina, et al.
Cancer Research|August 10, 2013
Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progressionTarah M Regan Anderson, Danielle L Peacock, Andrea R Daniel, et al.
Endocrinology|May 24, 2023
Glucocorticoid Receptors Drive Breast Cancer Cell Migration and Metabolic Reprogramming via PDK4Amy R Dwyer, Carlos Perez Kerkvliet, Thu H Truong, et al.
Oncotarget|October 8, 2016
A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activityYao Huang, David J Burns, Benjamin E Rich, et al.
Pageof 10